Home Featured Page 269

Featured

Latest

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

Lobe Sciences Announces Filing of PCT Application

BetterLife Files Patent for Invention of Novel Subcutaneous Implant to Prevent...

Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation...

Delix Therapeutics Co-Founder Publishes Groundbreaking Study Demonstrating Therapeutic Potential for a...

Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint...

PharmaDrug Announces First FDA Orphan Drug Designation of DMT for the...

COMPASS Pathways launches proposed public offering

Mystical Encounters, With and Without Drugs

How To Talk With Your Kids About Psychedelics

Lobe Sciences Enters into Joint Venture with Virtual Psychedelics Incorporated to...

EDITOR PICKS

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine,...

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.